The main functions and efficacy of adagrasib (Krazati) and its efficacy data in KRAS mutated lung cancer

Adagrasiib (Krazati) is an oral small molecule KRAS G12C inhibitor that specifically targets patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). KRASgene mutation is one of the most common driver gene mutations in NSCLC, among which G12C mutation accounts for about 40% of all KRAS mutations. KRAS G12Cmutation promotes tumor cell proliferation and survival through abnormal activation of the RAS-RAF-MEK-ERK signaling pathway, thereby driving tumor occurrence and progression. Adagarasib forms covalent binding with specific cysteine u200bu200bresidues of KRAS G12C protein to achieve selective inhibition and block downstream signaling, thereby inhibiting tumor cell proliferation and inducing apoptosis.

In terms of clinical efficacy, adagrasib showed significant efficacy in advanced or metastatic NSCLC. An early phase I/II clinical trial showed that adagrasib monotherapy achieved an objective response rate (ORR) Between 35% and 45%, the disease control rate (DCR) exceeds 80%. Tumor shrinkage can be observed in most patients within weeks of starting treatment, and some patients can achieve long-term disease stabilization, indicating the drug's important value in controlling KRAS G12C mutation-driven tumor progression.

Further analysis of the efficacy data showed that adagrasib performed differently in different subgroups of patients. Patients who have previously received immune checkpoint inhibitors or platinum-based chemotherapy have also shown impressive response rates in terms of efficacy; at the same time, for patients with brain metastases, some studies have shown that the drug also has a certain effect on central nervous system lesions and can delay the progression of brain metastases. Overall, adagrasib can provide new treatment options for patients with advanced KRAS G12C mutationNSCLC, especially for patients who are ineffective or resistant to traditional targeted drugs.

In terms of safety, adagrasib is well tolerated, with common adverse reactions including mild to moderate fatigue, nausea, diarrhea, muscle pain and mild abnormalities in hematological indicators. Most adverse reactions can be controlled through symptomatic treatment or dose adjustment without affecting the continuity of treatment. During the medication process, doctors usually make individualized dose adjustments based on the patient's age, underlying diseases, and concomitant medications to ensure maximum efficacy and reduce the risk of side effects.

In summary, adagrasib (Krazati), as one of the first small molecule inhibitors targeting KRAS G12C mutations, achieves tumor growth control and induction of apoptosis by specifically inhibiting KRAS G12C protein and its downstream signaling pathways. In patients with KRAS G12C mutation-positive non-small cell lung cancer, adagrasib demonstrated promising objective response and disease control rates and was well tolerated. Its emergence provides a new precision treatment strategy for this type of patients with high incidence of driver mutations, brings more hope to clinical practice, and also promotes the development and innovation in the field of KRAS targeted therapy.

Reference link:https://www.drugs.com